Lck Inhibitor

• CAT Number: I005078
• CAS Number: 847950-09-8
• Molecular Formula: C31H30N8O
• Molecular Weight: 530.60
• Purity: ≥95%
• Synonyms: 6-(2,6-dimethylphenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)benzo[4,5]imidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one
• Target: Src
• Solubility: in DMSO > 10 mM
• Storage: Store at -20°C
• IC50: 7 nM
• IUPAC Name: 9-(2,6-dimethylphenyl)-4-[4-(4-methylpiperazin-1-yl)anilino]-1,3,5,9,11-pentazatetracyclo[8.7.0.02,7.012,17]heptadeca-2,4,6,10,12,14,16-heptaen-8-one
• InChI: InChI=1S/C31H30N8O/c1-20-7-6-8-21(2)27(20)39-29(40)24-19-32-30(35-28(24)38-26-10-5-4-9-25(26)34-31(38)39)33-22-11-13-23(14-12-22)37-17-15-36(3)16-18-37/h4-14,19H,15-18H2,1-3H3,(H,32,33,35)
• InChIKey: BHJJWVDKNXABFS-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)C)N2C(=O)C3=CN=C(N=C3N4C2=NC5=CC=CC=C54)NC6=CC=C(C=C6)N7CCN(CC7)C

Lck inhibitors（Cat No.:I005078）are compounds that target and inhibit the activity of Lck (lymphocyte-specific protein tyrosine kinase), a key enzyme in T cell signaling. Lck plays a critical role in the activation of T cells during immune responses, including the initiation of T cell receptor (TCR) signaling. By inhibiting Lck, these compounds can suppress T cell activation, which has therapeutic potential in autoimmune diseases, organ transplant rejection, and certain cancers. Lck inhibitors are also being investigated in the context of immunotherapy, aiming to modulate immune responses in diseases such as rheumatoid arthritis and cancer.